Emiel van der Kouwe

List of Publications by Year
in descending order

10	275	1307594 7	1588992 8
papers	citations	h-index	g-index

10	10	10	562
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. Lancet Haematology,the, 2017, 4, e595-e606.	4.6	130
2	Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. Cancer Discovery, 2022, 12, 372-387.	9.4	77
3	Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML. Blood, 2021, 138, 1331-1344.	1.4	19
4	RUNX1-ETO: Attacking the Epigenome for Genomic Instable Leukemia. International Journal of Molecular Sciences, 2019, 20, 350.	4.1	17
5	IL2RA Promotes Aggressiveness and Stem Cellâ€“Related Properties of Acute Myeloid Leukemia. Cancer Research, 2020, 80, 4527-4539.	0.9	12
6	Core-binding factor leukemia hijacks the T-cellâ€“prone PU.1 antisense promoter. Blood, 2021, 138, 1345-1358.	1.4	12
7	Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia. Haematologica, 2021, 106, 2251-2256.	3.5	7
8	Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial. Blood, 2020, 136, 2-4.	1.4	1
9	Next-Generation Functional Drug Screening for Patients with Aggressive Hematologic Malignancies. Blood, 2017, 130, 855-855.	1.4	0
10	Core Binding Factor Leukemias Utilize a Physiologic Sense/Antisense Promoter Switch Employed By T-Cells. Blood, 2020, 136, 40-41.	1.4	0